Boston Scientific Corp (BSX) Stock Analysis

BSX- NYSE (USA) Also traded in: Germany
Boston Scientific Corp

Currently 1/5

Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$28.69

0(0%) Volume: 3,247,846 1:08AM EDT

Avg Vol (1m): 5,147,083

2 Medium Warning Signs

Market Cap : 39.37 B	Enterprise Value : 45.01 B	P/E (TTM) : 49.47	P/B : 5.43

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Also traded in: Germany

Financial Strength : 4/10

		vs industry	vs history
Cash-to-Debt	0.03	BSX's Cash-to-Debt is ranked lower than 96% of the 323 Companies in the Global Medical Devices industry. ( Industry Median: 2.54 vs. BSX: 0.03 ) Ranked among companies with meaningful Cash-to-Debt only. =GURUF("BSX","Cash-to-Debt")	BSX' s Cash-to-Debt Range Over the Past 10 Years Min: 0.03 Med: 0.16 Max: 4.69 Current: 0.03 0.03 - 4.69 =GURUF("BSX","Cash-to-Debt")
Equity-to-Asset	0.39	BSX's Equity-to-Asset is ranked lower than 81% of the 300 Companies in the Global Medical Devices industry. ( Industry Median: 0.65 vs. BSX: 0.39 ) Ranked among companies with meaningful Equity-to-Asset only. =GURUF("BSX","Equity-to-Asset")	BSX' s Equity-to-Asset Range Over the Past 10 Years Min: 0.18 Med: 0.51 Max: 0.83 Current: 0.39 0.18 - 0.83 =GURUF("BSX","Equity-to-Asset")
Debt-to-Equity	0.81	BSX's Debt-to-Equity is ranked lower than 81% of the 204 Companies in the Global Medical Devices industry. ( Industry Median: 0.29 vs. BSX: 0.81 ) Ranked among companies with meaningful Debt-to-Equity only. =GURUF("BSX","Debt-to-Equity")	BSX' s Debt-to-Equity Range Over the Past 10 Years Min: 0.06 Med: 0.52 Max: 3.64 Current: 0.81 0.06 - 3.64 =GURUF("BSX","Debt-to-Equity")
Interest Coverage	4.66	BSX's Interest Coverage is ranked lower than 92% of the 220 Companies in the Global Medical Devices industry. ( Industry Median: 73.23 vs. BSX: 4.66 ) Ranked among companies with meaningful Interest Coverage only. =GURUF("BSX","Interest Coverage")	BSX' s Interest Coverage Range Over the Past 10 Years Min: 0.37 Med: 1.92 Max: 4.66 Current: 4.66 0.37 - 4.66 =GURUF("BSX","Interest Coverage")

Piotroski F-Score: 6
Altman Z-Score: 2.08
Beneish M-Score: -2.41
WACC vs ROIC	7.63% 10.06% WACC ROIC

Profitability & Growth : 5/10

		vs industry	vs history
Operating Margin %	12.36	BSX's Operating Margin % is ranked higher than 58% of the 303 Companies in the Global Medical Devices industry. ( Industry Median: 3.45 vs. BSX: 12.36 ) Ranked among companies with meaningful Operating Margin % only. =GURUF("BSX","Operating Margin %")	BSX' s Operating Margin % Range Over the Past 10 Years Min: -53.36 Med: -4.23 Max: 12.36 Current: 12.36 -53.36 - 12.36 =GURUF("BSX","Operating Margin %")
Net Margin %	9.04	BSX's Net Margin % is ranked higher than 60% of the 303 Companies in the Global Medical Devices industry. ( Industry Median: 1.77 vs. BSX: 9.04 ) Ranked among companies with meaningful Net Margin % only. =GURUF("BSX","Net Margin %")	BSX' s Net Margin % Range Over the Past 10 Years Min: -56.12 Med: -4.56 Max: 9.04 Current: 9.04 -56.12 - 9.04 =GURUF("BSX","Net Margin %")
ROE %	11.68	BSX's ROE % is ranked higher than 61% of the 295 Companies in the Global Medical Devices industry. ( Industry Median: 2.13 vs. BSX: 11.68 ) Ranked among companies with meaningful ROE % only. =GURUF("BSX","ROE %")	BSX' s ROE % Range Over the Past 10 Years Min: -44.65 Med: -3.5 Max: 11.68 Current: 11.68 -44.65 - 11.68 =GURUF("BSX","ROE %")
ROA %	4.38	BSX's ROA % is ranked higher than 58% of the 324 Companies in the Global Medical Devices industry. ( Industry Median: 0.49 vs. BSX: 4.38 ) Ranked among companies with meaningful ROA % only. =GURUF("BSX","ROA %")	BSX' s ROA % Range Over the Past 10 Years Min: -21.16 Med: -1.48 Max: 4.38 Current: 4.38 -21.16 - 4.38 =GURUF("BSX","ROA %")
ROC (Joel Greenblatt) %	60.05	BSX's ROC (Joel Greenblatt) % is ranked higher than 73% of the 321 Companies in the Global Medical Devices industry. ( Industry Median: 6.15 vs. BSX: 60.05 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. =GURUF("BSX","ROC (Joel Greenblatt) %")	BSX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years Min: -144.7 Med: -14.88 Max: 60.05 Current: 60.05 -144.7 - 60.05 =GURUF("BSX","ROC (Joel Greenblatt) %")
3-Year Revenue Growth Rate	4.60	BSX's 3-Year Revenue Growth Rate is ranked lower than 51% of the 239 Companies in the Global Medical Devices industry. ( Industry Median: 5.30 vs. BSX: 4.60 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. =GURUF("BSX","3-Year Revenue Growth Rate")	BSX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years Min: -10.5 Med: 4.6 Max: 29 Current: 4.6 -10.5 - 29 =GURUF("BSX","3-Year Revenue Growth Rate")
3-Year EBITDA Growth Rate	14.70	BSX's 3-Year EBITDA Growth Rate is ranked higher than 59% of the 210 Companies in the Global Medical Devices industry. ( Industry Median: 6.30 vs. BSX: 14.70 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. =GURUF("BSX","3-Year EBITDA Growth Rate")	BSX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years Min: -71.1 Med: 14.7 Max: 271.1 Current: 14.7 -71.1 - 271.1 =GURUF("BSX","3-Year EBITDA Growth Rate")

GuruFocus has detected 2 Warning Signs with Boston Scientific Corp $BSX.

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

» BSX's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26 Est.)

Revenue & Net Income

Cash & Debt

Operating Cash Flow & Free Cash Flow

Operating Cash Flow & Net Income

» BSX's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades

Q3 2016

Q4 2016

Q1 2017

Q2 2017

» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Select Gurus: | Basic | Premium

| Premium Plus

Guru	Date	Trades	Impact to Portfolio	Price Range * (?)	Current Price	Change from Average	Current Shares
Vanguard Health Care Fund	2017-06-30	Reduce -2.73%	0.06%	$24.42 - $28.25	$ 28.69	8%	41,119,293
David Tepper	2017-06-30	Reduce -32.19%	0.44%	$24.42 - $28.25	$ 28.69	8%	2,264,900
Julian Robertson	2017-06-30	Add 18.83%	0.92%	$24.42 - $28.25	$ 28.69	8%	1,069,500
Mario Gabelli	2017-06-30	Reduce -11.91%	0.01%	$24.42 - $28.25	$ 28.69	8%	551,059
Dodge & Cox	2017-06-30	Reduce -1.34%		$24.42 - $28.25	$ 28.69	8%	324,255
Michael Price	2017-06-30	Reduce -41.00%	0.63%	$24.42 - $28.25	$ 28.69	8%	295,000
Joel Greenblatt	2017-06-30	Reduce -98.52%	0.52%	$24.42 - $28.25	$ 28.69	8%	24,597
Vanguard Health Care Fund	2017-03-31	Reduce -3.65%	0.08%	$21.88 - $25.41	$ 28.69	18%	42,272,393
David Tepper	2017-03-31	Add 507.27%	1.14%	$21.88 - $25.41	$ 28.69	18%	3,340,000
Joel Greenblatt	2017-03-31	Add 1574.40%	0.5%	$21.88 - $25.41	$ 28.69	18%	1,664,082
Julian Robertson	2017-03-31	New Buy	4.22%	$21.88 - $25.41	$ 28.69	18%	900,000
Mario Gabelli	2017-03-31	Reduce -4.22%		$21.88 - $25.41	$ 28.69	18%	625,559
Michael Price	2017-03-31	Reduce -28.57%	0.53%	$21.88 - $25.41	$ 28.69	18%	500,000
Dodge & Cox	2017-03-31	Reduce -11.57%		$21.88 - $25.41	$ 28.69	18%	328,655
John Paulson	2017-03-31	Sold Out	0.08%	$21.88 - $25.41	$ 28.69	18%	0
Vanguard Health Care Fund	2016-12-31	Reduce -5.69%	0.14%	$20.09 - $23.77	$ 28.69	31%	43,872,669
Mario Gabelli	2016-12-31	Reduce -2.96%		$20.09 - $23.77	$ 28.69	31%	653,146
David Tepper	2016-12-31	New Buy	0.21%	$20.09 - $23.77	$ 28.69	31%	550,000
Dodge & Cox	2016-12-31	Reduce -2.74%		$20.09 - $23.77	$ 28.69	31%	371,671
John Paulson	2016-12-31	Reduce -29.76%	0.03%	$20.09 - $23.77	$ 28.69	31%	288,000
Joel Greenblatt	2016-12-31	New Buy	0.03%	$20.09 - $23.77	$ 28.69	31%	99,384
Vanguard Health Care Fund	2016-09-30	Reduce -13.24%	0.35%	$23.11 - $24.48	$ 28.69	20%	46,520,049
Michael Price	2016-09-30	Reduce -22.22%	0.62%	$23.11 - $24.48	$ 28.69	20%	700,000
Mario Gabelli	2016-09-30	Reduce -2.14%		$23.11 - $24.48	$ 28.69	20%	673,046
John Paulson	2016-09-30	Add 336.17%	0.08%	$23.11 - $24.48	$ 28.69	20%	410,000
Dodge & Cox	2016-09-30	Reduce -0.73%		$23.11 - $24.48	$ 28.69	20%	382,130

More recent guru trades are included for Premium Members only!!

More recent guru trades are included for USA Subscribe Members only!!

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry:	Medical Devices » Medical Devices NAICS: 339112 SIC: 3841
Compare:	NAS:ISRG, NYSE:SYK, NYSE:EW, NYSE:ZBH, NAS:ALGN, NYSE:TFX, NYSE:VAR, NAS:ABMD, NAS:MASI, NAS:IART, NYSE:PEN, NAS:NUVA, NYSE:GMED, NYSE:NVRO, NAS:INGN, NAS:SPNC, NAS:MDXG, NYSE:ITGR, NAS:CNMD, NAS:BABY » details
Traded in other countries:	BSX.Germany,
Headquarter Location:	USA

Boston Scientific Corp is a developer, manufacturer and marketer of medical devices. The firm markets its devices to health-care professionals and institutions globally.

Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract tests, and treatment of incontinence. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Ratios

		vs industry	vs history
PE Ratio	49.46	BSX's PE Ratio is ranked lower than 84% of the 179 Companies in the Global Medical Devices industry. ( Industry Median: 30.71 vs. BSX: 49.46 ) Ranked among companies with meaningful PE Ratio only. =GURUF("BSX","PE Ratio")	BSX' s PE Ratio Range Over the Past 10 Years Min: 13.87 Med: 45.39 Max: 404.33 Current: 49.46 13.87 - 404.33 =GURUF("BSX","PE Ratio")
Forward PE Ratio	20.88	BSX's Forward PE Ratio is ranked higher than 71% of the 49 Companies in the Global Medical Devices industry. ( Industry Median: 25.64 vs. BSX: 20.88 ) Ranked among companies with meaningful Forward PE Ratio only. =GURUF("BSX","Forward PE Ratio")	N/A
PE Ratio without NRI	49.46	BSX's PE Ratio without NRI is ranked lower than 84% of the 178 Companies in the Global Medical Devices industry. ( Industry Median: 31.10 vs. BSX: 49.46 ) Ranked among companies with meaningful PE Ratio without NRI only. =GURUF("BSX","PE Ratio without NRI")	BSX' s PE Ratio without NRI Range Over the Past 10 Years Min: 13.87 Med: 45.39 Max: 404.33 Current: 49.46 13.87 - 404.33 =GURUF("BSX","PE Ratio without NRI")
Price-to-Owner-Earnings	36.28	BSX's Price-to-Owner-Earnings is ranked lower than 67% of the 109 Companies in the Global Medical Devices industry. ( Industry Median: 36.31 vs. BSX: 36.28 ) Ranked among companies with meaningful Price-to-Owner-Earnings only. =GURUF("BSX","Price-to-Owner-Earnings")	BSX' s Price-to-Owner-Earnings Range Over the Past 10 Years Min: 11.58 Med: 43.6 Max: 985.26 Current: 36.28 11.58 - 985.26 =GURUF("BSX","Price-to-Owner-Earnings")
PB Ratio	5.43	BSX's PB Ratio is ranked lower than 74% of the 291 Companies in the Global Medical Devices industry. ( Industry Median: 2.92 vs. BSX: 5.43 ) Ranked among companies with meaningful PB Ratio only. =GURUF("BSX","PB Ratio")	BSX' s PB Ratio Range Over the Past 10 Years Min: 0.59 Med: 1.45 Max: 5.49 Current: 5.43 0.59 - 5.49 =GURUF("BSX","PB Ratio")
PS Ratio	4.54	BSX's PS Ratio is ranked lower than 64% of the 290 Companies in the Global Medical Devices industry. ( Industry Median: 3.32 vs. BSX: 4.54 ) Ranked among companies with meaningful PS Ratio only. =GURUF("BSX","PS Ratio")	BSX' s PS Ratio Range Over the Past 10 Years Min: 1.02 Med: 2.22 Max: 4.59 Current: 4.54 1.02 - 4.59 =GURUF("BSX","PS Ratio")
Price-to-Free-Cash-Flow	126.40	BSX's Price-to-Free-Cash-Flow is ranked lower than 81% of the 110 Companies in the Global Medical Devices industry. ( Industry Median: 32.13 vs. BSX: 126.40 ) Ranked among companies with meaningful Price-to-Free-Cash-Flow only. =GURUF("BSX","Price-to-Free-Cash-Flow")	BSX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years Min: 7.21 Med: 21.01 Max: 220 Current: 126.4 7.21 - 220 =GURUF("BSX","Price-to-Free-Cash-Flow")
Price-to-Operating-Cash-Flow	54.03	BSX's Price-to-Operating-Cash-Flow is ranked lower than 81% of the 135 Companies in the Global Medical Devices industry. ( Industry Median: 19.50 vs. BSX: 54.03 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. =GURUF("BSX","Price-to-Operating-Cash-Flow")	BSX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years Min: 5.75 Med: 16 Max: 62.72 Current: 54.03 5.75 - 62.72 =GURUF("BSX","Price-to-Operating-Cash-Flow")
EV-to-EBIT	46.27	BSX's EV-to-EBIT is ranked lower than 93% of the 177 Companies in the Global Medical Devices industry. ( Industry Median: 24.67 vs. BSX: 46.27 ) Ranked among companies with meaningful EV-to-EBIT only. =GURUF("BSX","EV-to-EBIT")	BSX' s EV-to-EBIT Range Over the Past 10 Years Min: -2577.3 Med: -3.7 Max: 25838 Current: 46.27 -2577.3 - 25838 =GURUF("BSX","EV-to-EBIT")
EV-to-EBITDA	29.40	BSX's EV-to-EBITDA is ranked lower than 86% of the 183 Companies in the Global Medical Devices industry. ( Industry Median: 17.99 vs. BSX: 29.40 ) Ranked among companies with meaningful EV-to-EBITDA only. =GURUF("BSX","EV-to-EBITDA")	BSX' s EV-to-EBITDA Range Over the Past 10 Years Min: -680.1 Med: 9 Max: 242.5 Current: 29.4 -680.1 - 242.5 =GURUF("BSX","EV-to-EBITDA")
EV-to-Revenue	5.16	BSX's EV-to-Revenue is ranked lower than 63% of the 296 Companies in the Global Medical Devices industry. ( Industry Median: 3.70 vs. BSX: 5.16 ) Ranked among companies with meaningful EV-to-Revenue only. =GURUF("BSX","EV-to-Revenue")	BSX' s EV-to-Revenue Range Over the Past 10 Years Min: 1 Med: 2.9 Max: 5.3 Current: 5.16 1 - 5.3 =GURUF("BSX","EV-to-Revenue")
Current Ratio	0.75	BSX's Current Ratio is ranked lower than 88% of the 319 Companies in the Global Medical Devices industry. ( Industry Median: 2.64 vs. BSX: 0.75 ) Ranked among companies with meaningful Current Ratio only. =GURUF("BSX","Current Ratio")	BSX' s Current Ratio Range Over the Past 10 Years Min: 0.52 Med: 1.56 Max: 7.77 Current: 0.75 0.52 - 7.77 =GURUF("BSX","Current Ratio")
Quick Ratio	0.51	BSX's Quick Ratio is ranked lower than 90% of the 319 Companies in the Global Medical Devices industry. ( Industry Median: 1.92 vs. BSX: 0.51 ) Ranked among companies with meaningful Quick Ratio only. =GURUF("BSX","Quick Ratio")	BSX' s Quick Ratio Range Over the Past 10 Years Min: 0.33 Med: 1.2 Max: 6.29 Current: 0.51 0.33 - 6.29 =GURUF("BSX","Quick Ratio")
Days Inventory	144.19	BSX's Days Inventory is ranked lower than 55% of the 285 Companies in the Global Medical Devices industry. ( Industry Median: 128.08 vs. BSX: 144.19 ) Ranked among companies with meaningful Days Inventory only. =GURUF("BSX","Days Inventory")	BSX' s Days Inventory Range Over the Past 10 Years Min: 113.61 Med: 133.18 Max: 164.78 Current: 144.19 113.61 - 164.78 =GURUF("BSX","Days Inventory")
Days Sales Outstanding	60.49	BSX's Days Sales Outstanding is ranked higher than 60% of the 273 Companies in the Global Medical Devices industry. ( Industry Median: 68.17 vs. BSX: 60.49 ) Ranked among companies with meaningful Days Sales Outstanding only. =GURUF("BSX","Days Sales Outstanding")	BSX' s Days Sales Outstanding Range Over the Past 10 Years Min: 58.51 Med: 61.98 Max: 66.79 Current: 60.49 58.51 - 66.79 =GURUF("BSX","Days Sales Outstanding")
Days Payable	55.01	BSX's Days Payable is ranked higher than 50% of the 258 Companies in the Global Medical Devices industry. ( Industry Median: 54.45 vs. BSX: 55.01 ) Ranked among companies with meaningful Days Payable only. =GURUF("BSX","Days Payable")	BSX' s Days Payable Range Over the Past 10 Years Min: 21.66 Med: 35.22 Max: 67.31 Current: 55.01 21.66 - 67.31 =GURUF("BSX","Days Payable")

Buy Back

		vs industry	vs history
3-Year Average Share Buyback Ratio	-1.00	BSX's 3-Year Average Share Buyback Ratio is ranked higher than 70% of the 226 Companies in the Global Medical Devices industry. ( Industry Median: -4.10 vs. BSX: -1.00 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. =GURUF("BSX","3-Year Average Share Buyback Ratio")	BSX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years Min: -25.9 Med: -1 Max: 4.6 Current: -1 -25.9 - 4.6 =GURUF("BSX","3-Year Average Share Buyback Ratio")

Valuation & Return

		vs industry	vs history
Price-to-Intrinsic-Value-Projected-FCF	3.07	BSX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than 60% of the 141 Companies in the Global Medical Devices industry. ( Industry Median: 2.41 vs. BSX: 3.07 ) Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only. =GURUF("BSX","Price-to-Intrinsic-Value-Projected-FCF")	BSX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years Min: 0.51 Med: 1.55 Max: 500 Current: 3.07 0.51 - 500 =GURUF("BSX","Price-to-Intrinsic-Value-Projected-FCF")
Price-to-Median-PS-Value	2.05	BSX's Price-to-Median-PS-Value is ranked lower than 87% of the 275 Companies in the Global Medical Devices industry. ( Industry Median: 1.01 vs. BSX: 2.05 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. =GURUF("BSX","Price-to-Median-PS-Value")	BSX' s Price-to-Median-PS-Value Range Over the Past 10 Years Min: 0.48 Med: 1.48 Max: 4.29 Current: 2.05 0.48 - 4.29 =GURUF("BSX","Price-to-Median-PS-Value")
Price-to-Peter-Lynch-Fair-Value	1.62	BSX's Price-to-Peter-Lynch-Fair-Value is ranked lower than 99.99% of the 56 Companies in the Global Medical Devices industry. ( Industry Median: 2.12 vs. BSX: 1.62 ) Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only. =GURUF("BSX","Price-to-Peter-Lynch-Fair-Value")	BSX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years Min: 0 Med: 1.63 Max: 12.18 Current: 1.62 0 - 12.18 =GURUF("BSX","Price-to-Peter-Lynch-Fair-Value")
Earnings Yield (Greenblatt) %	2.15	BSX's Earnings Yield (Greenblatt) % is ranked lower than 51% of the 323 Companies in the Global Medical Devices industry. ( Industry Median: 1.25 vs. BSX: 2.15 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. =GURUF("BSX","Earnings Yield (Greenblatt) %")	BSX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years Min: -34.3 Med: -1.3 Max: 9.1 Current: 2.15 -34.3 - 9.1 =GURUF("BSX","Earnings Yield (Greenblatt) %")
Forward Rate of Return (Yacktman) %	42.23	BSX's Forward Rate of Return (Yacktman) % is ranked higher than 95% of the 125 Companies in the Global Medical Devices industry. ( Industry Median: 8.78 vs. BSX: 42.23 ) Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only. =GURUF("BSX","Forward Rate of Return (Yacktman) %")	BSX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years Min: 3.1 Med: 7 Max: 42.23 Current: 42.23 3.1 - 42.23 =GURUF("BSX","Forward Rate of Return (Yacktman) %")

More Statistics

Revenue (TTM) (Mil) $	8,713.00
EPS (TTM) $	0.58
Beta	0.97
Short Percentage of Float	1.03%
52-Week Range $	19.67 - 29.40
Shares Outstanding (Mil)	1,372.13

Analyst Estimate

	Dec17	Dec18	Dec19
Revenue (Mil $)	8,904	9,494	10,137
EPS ($)	1.26	1.40	1.53
EPS without NRI ($)	1.26	1.40	1.53
EPS Growth Rate (Future 3Y To 5Y Estimate)	13.20%
Dividends per Share ($)

» More Articles for BSX

Headlines

Articles On GuruFocus.com

Boston Scientific To Participate In Morgan Stanley Global Healthcare Conference Aug 28 2017

Boston Scientific To Participate In Wells Fargo 2017 Healthcare Conference Aug 21 2017

Boston Scientific To Participate In 2017 Canaccord Genuity Growth Conference Jul 31 2017

Boston Scientific Receives CE Mark for Vercise™ Gevia™ Deep Brain Stimulation System Jun 06 2017

Boston Scientific Announces Positive Outcomes From Prospective Study Of Bronchial Thermoplasty May 24 2017

Goldman Sachs Rates Health Care Stocks May 17 2017

The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global May 16 2017

Julian Robertson Buys Adobe and Sells Apple in 1st Quarter May 15 2017

Boston Scientific Announces Positive European Registry Results For WATCHMAN™ Left Atrial Appendage May 12 2017

New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Trad May 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

Value Screens

Downloads | Tools

Strategies

Market Valuation

By Country

Articles

Submit Articles

Categories

Financial Strength : 4/10

Profitability & Growth : 5/10

Financials (Next Earnings Date: 2017-10-26 Est.)

Warning Signs

Guru Trades

BSX Guru Trades in Q3 2016

BSX Guru Trades in Q4 2016

BSX Guru Trades in Q1 2017

BSX Guru Trades in Q2 2017

Insider Trades

Latest Guru Trades with BSX

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Top Ranked Articles about Boston Scientific Corp

Ratios

Buy Back

Valuation & Return

More Statistics

Analyst Estimate

Headlines

Personalized Checklist

Value Screens

Downloads | Tools

Strategies

Market Valuation

By Country

Articles

Submit Articles

Categories

Financial Strength : 4/10

Profitability & Growth : 5/10

Financials .earnings_date { color: #000000; font-size: 12px; font-weight: normal; } (Next Earnings Date: 2017-10-26 Est.)

Warning Signs

Guru Trades

BSX Guru Trades in Q3 2016

BSX Guru Trades in Q4 2016

BSX Guru Trades in Q1 2017

BSX Guru Trades in Q2 2017

Insider Trades

Latest Guru Trades with BSX

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Top Ranked Articles about Boston Scientific Corp

Ratios

Buy Back

Valuation & Return

More Statistics

Analyst Estimate

Headlines

Personalized Checklist

Financials (Next Earnings Date: 2017-10-26 Est.)